Enviar búsqueda
Cargar
View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval next month as a second-line therapy?
•
0 recomendaciones
•
259 vistas
Rhonda Greenapple
Seguir
Denunciar
Compartir
Denunciar
Compartir
1 de 2
Descargar ahora
Descargar para leer sin conexión
Recomendados
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...
Rhonda Greenapple
Project
Project
PRINTDESK by Dan
Gluco Center Concept Paper 2009
Gluco Center Concept Paper 2009
Manas Kanungo, MBA, MS Bioengineering
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Rhonda Greenapple
Report in political science
Report in political science
PRINTDESK by Dan
Final
Final
PRINTDESK by Dan
First Word Pharma View Points Commercial Prospects In The Obesity Market ...
First Word Pharma View Points Commercial Prospects In The Obesity Market ...
Rhonda Greenapple
Analysis: Drug Costs Become Bigger Issue In Cancer Care
Analysis: Drug Costs Become Bigger Issue In Cancer Care
Rhonda Greenapple
Recomendados
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...
Rhonda Greenapple
Project
Project
PRINTDESK by Dan
Gluco Center Concept Paper 2009
Gluco Center Concept Paper 2009
Manas Kanungo, MBA, MS Bioengineering
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Rhonda Greenapple
Report in political science
Report in political science
PRINTDESK by Dan
Final
Final
PRINTDESK by Dan
First Word Pharma View Points Commercial Prospects In The Obesity Market ...
First Word Pharma View Points Commercial Prospects In The Obesity Market ...
Rhonda Greenapple
Analysis: Drug Costs Become Bigger Issue In Cancer Care
Analysis: Drug Costs Become Bigger Issue In Cancer Care
Rhonda Greenapple
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Rhonda Greenapple
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Rhonda Greenapple
Payers likely to throw up hurdles to Pfizer\'s new RA drug
Payers likely to throw up hurdles to Pfizer\'s new RA drug
Rhonda Greenapple
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
Rhonda Greenapple
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Rhonda Greenapple
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Rhonda Greenapple
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Rhonda Greenapple
Vbcc Aco Article
Vbcc Aco Article
Rhonda Greenapple
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Rhonda Greenapple
Roadmap to reimbursement and access
Roadmap to reimbursement and access
Rhonda Greenapple
Más contenido relacionado
Más de Rhonda Greenapple
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Rhonda Greenapple
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Rhonda Greenapple
Payers likely to throw up hurdles to Pfizer\'s new RA drug
Payers likely to throw up hurdles to Pfizer\'s new RA drug
Rhonda Greenapple
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
Rhonda Greenapple
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Rhonda Greenapple
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Rhonda Greenapple
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Rhonda Greenapple
Vbcc Aco Article
Vbcc Aco Article
Rhonda Greenapple
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Rhonda Greenapple
Roadmap to reimbursement and access
Roadmap to reimbursement and access
Rhonda Greenapple
Más de Rhonda Greenapple
(10)
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Payers likely to throw up hurdles to Pfizer\'s new RA drug
Payers likely to throw up hurdles to Pfizer\'s new RA drug
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Vbcc Aco Article
Vbcc Aco Article
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Roadmap to reimbursement and access
Roadmap to reimbursement and access
Descargar ahora